While extremely interesting, it is also uncomfortable to think about the genetic stability of cultured induced pluripotent stem cells (iPSCs). Our team members Fabian Zanella and Raluca Marcu discussed this topic in a recent publication, and we are expanding some of those insights and highlighting how the approaches and technologies available at Pluristyx can help. […]
Exploring Genetic Stability in iPSCs Read More »
Introduction to Cryopreservation Cryopreservation, involving the preservation of cells and maintenance of biological states through suspension in a cryo-media at frozen temperatures, is today the bio-preservation technique of choice for advanced therapy supply chains (Jang et al., 2017, Rafiq et al., 2017). Compared to alternatives such as short term hypothermic preservation, cryopreservation offers extended hold
Cryopreservation (II): Cutting edge solutions Read More »
Chimeric antigen receptor (CAR) T-cell therapies are a novel class of targeted and personalized immunotherapy which have shown remarkable success to date in treating certain hematological malignancies, including certain types of leukemia and lymphoma. There are currently six commercially available CAR T-Cell therapies: Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Carvykti (Ghosh, 2023). There are a
FailSafe®: Engineered safety for tomorrow’s cell therapies Read More »
Introduction to Cryopreservation Cryopreservation describes the controlled process of freezing biological material at extremely low temperatures in order to discontinue biochemical reactions, including those associated with cell death and DNA damage, to allow long-term storage and/or transport. Given recent medical advances in cell-based therapies, the importance of cryopreservation continues to increase based on the necessity
